^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:AiRuiKa (camrelizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Medicine Matters Oncology
    Title:

    First-line camrelizumab plus chemo supported for Chinese nonsquamous NSCLC patients

    Published date:
    01/15/2021
    Excerpt:
    ...camrelizumab plus carboplatin and pemetrexed was approved as a new standard first-line therapeutic option for Chinese patients….the CameL trial indicates that progression-free survival (PFS) for Chinese patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) is improved with the first-line use of the PD-1 inhibitor camrelizumab alongside chemotherapy.
    Secondary therapy:
    carboplatin + pemetrexed